Minimal Residual Disease: Predicting and Preventing Relapse in Myeloma

In the evolving landscape of haematologic cancers, the concept of minimal residual disease, also known as measurable residual disease (MRD), has rapidly shifted from a theoretical indicator to a powerful, practice-changing tool. At the forefront of this shift is multiple myeloma (MM), where MRD has emerged as a highly sensitive measure of treatment response and a compelling surrogate marker for long-term outcomes.